Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia

Emily Silgard, M.S. Computational Linguistics, Vicky Sandhu, MD MPH, Elihu H. Estey, MD, Daniel Herman, MD, PhD

Blood (2015) 126 (23): 2602.

https://doi.org/10.1182/blood.V126.23.2602.2602

Published: 2015

Journal Articles

Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Colin Godwin, MD MPhil, Megan Othus, PhD, Vicky Sandhu, MD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 2277.

https://doi.org/10.1182/blood.V124.21.2277.2277

Published: 2014

Journal Articles

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Hanahlyn M Park, BSN, MN(c), Vicky Sandhu, MD MPH, Paul Fearn, MBA, PhDc), Kathleen Shannon Dorcy, RN, MN, PhD, Elihu H. Estey, MD, Emily Silgard, MS

Blood (2014) 124 (21): 1267.

https://doi.org/10.1182/blood.V124.21.1267.1267

Published: 2014

Journal Articles

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mazyar Shadman, MD MPH, Raya Mawad, MD, Carol Dean, MPH, BSN, Kathleen Shannon-Dorcy, RN,PhD, Vicky Sandhu, MD MPH, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, John Pagel, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3732.

https://doi.org/10.1182/blood.V124.21.3732.3732

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

NARROW

An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia

Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia

Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only